CR20220068A - Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr - Google Patents
Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atrInfo
- Publication number
- CR20220068A CR20220068A CR20220068A CR20220068A CR20220068A CR 20220068 A CR20220068 A CR 20220068A CR 20220068 A CR20220068 A CR 20220068A CR 20220068 A CR20220068 A CR 20220068A CR 20220068 A CR20220068 A CR 20220068A
- Authority
- CR
- Costa Rica
- Prior art keywords
- optionally substituted
- alkyl
- substituted
- morpholinopyridine
- derivatives
- Prior art date
Links
- XHPVOSNOIWGRQQ-UHFFFAOYSA-N 4-pyridin-2-ylmorpholine Chemical class C1COCCN1C1=CC=CC=N1 XHPVOSNOIWGRQQ-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen compuestos con la fórmula (I) o sales farmacéuticamente aceptables de estos, en donde — es un enlace simple, y cada Y es N o CR4 ; o — está ausente, y cada Y es NRY , carbonilo o (C(RY )2, en donde cada R1 es H o alquilo de C1-6 opcionalmente sustituido; R1 es alquilo de C1-6 opcionalmente sustituido o H; R3 es heteroarilo de C1-9 opcionalmente sustituido o alquilo de C1-6 heteroarilo de C1-9 opcionalmente sustituido; cada R4 es hidrógeno, halógeno, alquilo de C1-6 opcionalmente sustituido, alquenilo de C2-6 opcionalmente sustituido o alquinilo de C2-6 opcionalmente sustituido; X es hidrógeno o halógeno; y R2 es como se define en la reivindicación 1. También se describen composiciones farmacéuticas que contienen los compuestos con la fórmula (I) y métodos para su preparación. Los compuestos con la fórmula (I) pueden ser inhibidores de la proteína cinasa relacionada con ataxia telangiectasia y RAD-3 (ATR) y usarse para el tratamiento de enfermedades y afecciones tales como cánceres.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877177P | 2019-07-22 | 2019-07-22 | |
| PCT/CA2019/051539 WO2020087170A1 (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| PCT/CA2020/051014 WO2021012049A1 (en) | 2019-07-22 | 2020-07-22 | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220068A true CR20220068A (es) | 2022-06-30 |
Family
ID=74192632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220068A CR20220068A (es) | 2019-07-22 | 2020-07-22 | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220185809A1 (es) |
| EP (1) | EP4003993A4 (es) |
| JP (2) | JP7617076B2 (es) |
| KR (1) | KR20220035925A (es) |
| CN (1) | CN114174292B (es) |
| AU (1) | AU2020317381A1 (es) |
| BR (1) | BR112022000431A2 (es) |
| CA (1) | CA3148278A1 (es) |
| CO (1) | CO2022001853A2 (es) |
| CR (1) | CR20220068A (es) |
| EC (1) | ECSP22012347A (es) |
| IL (1) | IL289763A (es) |
| MX (1) | MX2022000854A (es) |
| PH (1) | PH12022550156A1 (es) |
| UA (1) | UA129807C2 (es) |
| WO (1) | WO2021012049A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20210281A (es) | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
| CA3164203A1 (en) * | 2019-12-11 | 2021-06-17 | Repare Therapeutics Inc. | Use of atr inhibitors in combination with parp inhibitors |
| BR112023022481A2 (pt) * | 2021-04-28 | 2024-02-15 | Repare Therapeutics Inc | Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica |
| MX2023014302A (es) * | 2021-06-04 | 2024-02-28 | Repare Therapeutics Inc | Formas cristalinas, composiciones que contienen las mismas y métodos para su uso. |
| KR20240041354A (ko) * | 2021-07-27 | 2024-03-29 | 릿츠뜨 메디시네스 엘티디 | 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 |
| CN113856764B (zh) * | 2021-10-29 | 2022-11-01 | 华中科技大学 | 一种过渡金属催化剂及其制备方法和应用 |
| CN116099390B (zh) * | 2022-11-14 | 2024-07-23 | 石河子大学 | 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用 |
| WO2024211696A1 (en) * | 2023-04-07 | 2024-10-10 | Biogen Ma Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025067111A1 (zh) * | 2023-09-27 | 2025-04-03 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025181153A1 (en) * | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202545519A (zh) * | 2024-05-15 | 2025-12-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795573B1 (en) * | 2009-12-31 | 2022-07-06 | Hutchison Medipharma Limited | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| JP5889875B2 (ja) * | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| ES2951688T3 (es) * | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013095761A1 (en) * | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
| TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| RS61688B1 (sr) * | 2015-04-29 | 2021-05-31 | Janssen Pharmaceutica Nv | Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora |
| JP6873145B2 (ja) * | 2016-01-14 | 2021-05-19 | バイエル・ファルマ・アクティエンゲゼルシャフト | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン |
| CR20210281A (es) * | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
-
2020
- 2020-07-22 MX MX2022000854A patent/MX2022000854A/es unknown
- 2020-07-22 UA UAA202200734A patent/UA129807C2/uk unknown
- 2020-07-22 CN CN202080052942.8A patent/CN114174292B/zh active Active
- 2020-07-22 CA CA3148278A patent/CA3148278A1/en active Pending
- 2020-07-22 BR BR112022000431A patent/BR112022000431A2/pt unknown
- 2020-07-22 EP EP20843290.6A patent/EP4003993A4/en active Pending
- 2020-07-22 JP JP2022504181A patent/JP7617076B2/ja active Active
- 2020-07-22 AU AU2020317381A patent/AU2020317381A1/en not_active Abandoned
- 2020-07-22 KR KR1020227004829A patent/KR20220035925A/ko not_active Ceased
- 2020-07-22 CR CR20220068A patent/CR20220068A/es unknown
- 2020-07-22 WO PCT/CA2020/051014 patent/WO2021012049A1/en not_active Ceased
- 2020-07-22 PH PH1/2022/550156A patent/PH12022550156A1/en unknown
-
2022
- 2022-01-11 IL IL289763A patent/IL289763A/en unknown
- 2022-01-20 US US17/580,207 patent/US20220185809A1/en active Pending
- 2022-02-16 EC ECSENADI202212347A patent/ECSP22012347A/es unknown
- 2022-02-22 CO CONC2022/0001853A patent/CO2022001853A2/es unknown
-
2025
- 2025-01-06 JP JP2025001996A patent/JP7758895B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022541825A (ja) | 2022-09-27 |
| JP2025061048A (ja) | 2025-04-10 |
| MX2022000854A (es) | 2022-02-10 |
| ECSP22012347A (es) | 2022-03-31 |
| CA3148278A1 (en) | 2021-01-28 |
| KR20220035925A (ko) | 2022-03-22 |
| AU2020317381A1 (en) | 2022-02-10 |
| BR112022000431A2 (pt) | 2022-03-03 |
| UA129807C2 (uk) | 2025-08-06 |
| WO2021012049A8 (en) | 2021-04-15 |
| EP4003993A4 (en) | 2023-01-18 |
| EP4003993A1 (en) | 2022-06-01 |
| CN114174292B (zh) | 2024-06-18 |
| PH12022550156A1 (en) | 2023-05-08 |
| WO2021012049A1 (en) | 2021-01-28 |
| CO2022001853A2 (es) | 2022-03-29 |
| US20220185809A1 (en) | 2022-06-16 |
| JP7617076B2 (ja) | 2025-01-17 |
| IL289763A (en) | 2022-03-01 |
| CN114174292A (zh) | 2022-03-11 |
| JP7758895B2 (ja) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001853A2 (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| PE20230825A1 (es) | Inhibidores de kras triciclicos fusionados | |
| AR130689A1 (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| UY26968A1 (es) | Agentes terapéuticos | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CL2012001699A1 (es) | Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos, inhibidores de cfms; proceso de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de enfermedades relacionadas con huesos, cancer, trastornos autoinmunes, enfermedades inflamatorias, entre otras. | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| EA200601364A1 (ru) | Производные хинолина и их применение в качестве ингибиторов микобактерий | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR040580A1 (es) | Derivados de pirazol heterobiciclico como inhibidores de la quinasa | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CO2020004669A2 (es) | Derivados de bencimidazol y sus usos | |
| MX389581B (es) | Compuestos que contienen nitrogeno sustituido. | |
| PA8589601A1 (es) | Derivados de indazol como antagonistas del crf | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
| TR200103789T2 (tr) | Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller. |